Immunoexperssion of cancer stem cell marker (CD44) in ameloblastoma
Background: Ameloblastoma is the most frequently encountered benign, locally invasive tumor. Attempts to surgically resect the tumor often leave small islands of tumor, which later result in recurrence in 50%-90% of cases. This has raised questions regarding the tumor cell populations that are respo...
Gespeichert in:
| Veröffentlicht in: | Journal of oral and maxillofacial pathology : JOMFP 2019-09, Vol.23 (3), p.400-406 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 406 |
|---|---|
| container_issue | 3 |
| container_start_page | 400 |
| container_title | Journal of oral and maxillofacial pathology : JOMFP |
| container_volume | 23 |
| creator | Vanje, Manjushri Tanveer, Shahela Ahmed, Syed Kumar, Shravan Vanje, Tejashree |
| description | Background: Ameloblastoma is the most frequently encountered benign, locally invasive tumor. Attempts to surgically resect the tumor often leave small islands of tumor, which later result in recurrence in 50%-90% of cases. This has raised questions regarding the tumor cell populations that are responsible for tumor growth and recurrence. In ameloblastoma, whether or not cancer stem-like cells are present remains undetermined. However, if cancer stem-like cells are present in ameloblastoma, it is important to identify which type of cell possesses the stem-like characteristics and is responsible for ameloblastoma progression and recurrence.
Aim: Our study aims at analyzing immunohistochemical staining to detect the expression of cancer stem cell (CSC) marker CD44 in relation to proliferative activity of tumor cells in histopathologically diagnosed cases of ameloblastoma variants and to derive a correlation between the CD44 expression and biologic behavior of the lesion.
Materials and Methods: A retrospective study, was conducted on total 25 cases ameloblastoma and were immunostained for CD44 expression. Results obtained were statistically analyzed.
Results: A positive correlation was observed between staining intensity of CD44 marker and the known biological behavior of the lesion. Intense staining reaction was found to be only in 8% cases, whereas 76% cases demonstrated moderate intensity and remaining 16% displayed mild immunoreactivity to CD44 marker. Staining location was more to be in stellate reticulum-like (SR-like) cells when compared to ameloblast-like (AB-like) cells. Intense immunostaining was localized in the small tumor follicles, especially in SR-like cells situated in close vicinity of peripheral AB-like cells whereas mild intensity of staining was observed in keratinizing areas.
Conclusion: CSCs marker positive expression in benign tumor like ameloblastoma may be responsible for its aggressiveness and recurrence. CD44 marker may be of great value in predicting the biological behavior and growth potential of ameloblastoma. |
| doi_str_mv | 10.4103/jomfp.JOMFP_152_17 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6948039</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A745199523</galeid><sourcerecordid>A745199523</sourcerecordid><originalsourceid>FETCH-LOGICAL-c473x-94ae8381386c5b14b6cb133a8ee4f9058abf772224cb95bdad5cff79b1dfe6ee3</originalsourceid><addsrcrecordid>eNp9ks1u1DAUhS0EosPAC7BAkdiURQb_TuINUjWlUFRUFiB1ZznOdclMbA92wpS3x2HaaooQ8sKS_Z3je-8xQi8JXnCC2dt1cHa7-HT5-eyLIoIqUj1CMyJlXTLJrh6jGZYVKzGVV0foWUprjEXNBX2KjhiRnBJKZmh17tzoA9xsIabUBV8EWxjtDcQiDeAKA31fOB03-eB4dcr5m6LzhXbQh6bXaQhOP0dPrO4TvLjd5-jb2fuvq4_lxeWH89XJRWl4xW5KyTXUrCasXhrREN4sTUMY0zUAtzLXphtbVZRSbhopmla3wlhbyYa0FpYAbI7e7X23Y-OgNeCHqHu1jV2u75cKulMPb3z3XV2Hn2opeY3zTObo-NYghh8jpEG5Lk0Nag9hTIoyJiu55GJCX_-FrsMYfW5vorCoBMEH1LXuQXXehvyumUzVScVFzkJkeo4W_6DyasF1JniwXT5_IKB7gYkhpQj2vkeC1RS9-hO9Oow-i14dTudecpd1Bk73wC70Q0570487iCqzGx92_7FWHGN190_Yb-V-w1Y</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2330575109</pqid></control><display><type>article</type><title>Immunoexperssion of cancer stem cell marker (CD44) in ameloblastoma</title><source>Medknow Open Access Medical Journals(OpenAccess)</source><source>PubMed Central Open Access</source><source>PubMed Central</source><source>EZB Electronic Journals Library</source><creator>Vanje, Manjushri ; Tanveer, Shahela ; Ahmed, Syed ; Kumar, Shravan ; Vanje, Tejashree</creator><creatorcontrib>Vanje, Manjushri ; Tanveer, Shahela ; Ahmed, Syed ; Kumar, Shravan ; Vanje, Tejashree</creatorcontrib><description>Background: Ameloblastoma is the most frequently encountered benign, locally invasive tumor. Attempts to surgically resect the tumor often leave small islands of tumor, which later result in recurrence in 50%-90% of cases. This has raised questions regarding the tumor cell populations that are responsible for tumor growth and recurrence. In ameloblastoma, whether or not cancer stem-like cells are present remains undetermined. However, if cancer stem-like cells are present in ameloblastoma, it is important to identify which type of cell possesses the stem-like characteristics and is responsible for ameloblastoma progression and recurrence.
Aim: Our study aims at analyzing immunohistochemical staining to detect the expression of cancer stem cell (CSC) marker CD44 in relation to proliferative activity of tumor cells in histopathologically diagnosed cases of ameloblastoma variants and to derive a correlation between the CD44 expression and biologic behavior of the lesion.
Materials and Methods: A retrospective study, was conducted on total 25 cases ameloblastoma and were immunostained for CD44 expression. Results obtained were statistically analyzed.
Results: A positive correlation was observed between staining intensity of CD44 marker and the known biological behavior of the lesion. Intense staining reaction was found to be only in 8% cases, whereas 76% cases demonstrated moderate intensity and remaining 16% displayed mild immunoreactivity to CD44 marker. Staining location was more to be in stellate reticulum-like (SR-like) cells when compared to ameloblast-like (AB-like) cells. Intense immunostaining was localized in the small tumor follicles, especially in SR-like cells situated in close vicinity of peripheral AB-like cells whereas mild intensity of staining was observed in keratinizing areas.
Conclusion: CSCs marker positive expression in benign tumor like ameloblastoma may be responsible for its aggressiveness and recurrence. CD44 marker may be of great value in predicting the biological behavior and growth potential of ameloblastoma.</description><identifier>ISSN: 0973-029X</identifier><identifier>EISSN: 1998-393X</identifier><identifier>DOI: 10.4103/jomfp.JOMFP_152_17</identifier><identifier>PMID: 31942121</identifier><language>eng</language><publisher>India: Wolters Kluwer India Pvt. Ltd</publisher><subject>Ameloblastoma ; Benign ; Cancer ; CD44 antigen ; Ethylenediaminetetraacetic acid ; Follicles ; Immunoreactivity ; Invasiveness ; Original ; Statistical analysis ; Stem cell research ; Stem cells ; Tumor cells</subject><ispartof>Journal of oral and maxillofacial pathology : JOMFP, 2019-09, Vol.23 (3), p.400-406</ispartof><rights>Copyright: © 2019 Journal of Oral and Maxillofacial Pathology.</rights><rights>COPYRIGHT 2019 Medknow Publications and Media Pvt. Ltd.</rights><rights>2019. This work is published under https://creativecommons.org/licenses/by-nc-sa/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>Copyright: © 2019 Journal of Oral and Maxillofacial Pathology 2019</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c473x-94ae8381386c5b14b6cb133a8ee4f9058abf772224cb95bdad5cff79b1dfe6ee3</citedby><cites>FETCH-LOGICAL-c473x-94ae8381386c5b14b6cb133a8ee4f9058abf772224cb95bdad5cff79b1dfe6ee3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6948039/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6948039/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,724,777,781,882,27439,27905,27906,53772,53774</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31942121$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Vanje, Manjushri</creatorcontrib><creatorcontrib>Tanveer, Shahela</creatorcontrib><creatorcontrib>Ahmed, Syed</creatorcontrib><creatorcontrib>Kumar, Shravan</creatorcontrib><creatorcontrib>Vanje, Tejashree</creatorcontrib><title>Immunoexperssion of cancer stem cell marker (CD44) in ameloblastoma</title><title>Journal of oral and maxillofacial pathology : JOMFP</title><addtitle>J Oral Maxillofac Pathol</addtitle><description>Background: Ameloblastoma is the most frequently encountered benign, locally invasive tumor. Attempts to surgically resect the tumor often leave small islands of tumor, which later result in recurrence in 50%-90% of cases. This has raised questions regarding the tumor cell populations that are responsible for tumor growth and recurrence. In ameloblastoma, whether or not cancer stem-like cells are present remains undetermined. However, if cancer stem-like cells are present in ameloblastoma, it is important to identify which type of cell possesses the stem-like characteristics and is responsible for ameloblastoma progression and recurrence.
Aim: Our study aims at analyzing immunohistochemical staining to detect the expression of cancer stem cell (CSC) marker CD44 in relation to proliferative activity of tumor cells in histopathologically diagnosed cases of ameloblastoma variants and to derive a correlation between the CD44 expression and biologic behavior of the lesion.
Materials and Methods: A retrospective study, was conducted on total 25 cases ameloblastoma and were immunostained for CD44 expression. Results obtained were statistically analyzed.
Results: A positive correlation was observed between staining intensity of CD44 marker and the known biological behavior of the lesion. Intense staining reaction was found to be only in 8% cases, whereas 76% cases demonstrated moderate intensity and remaining 16% displayed mild immunoreactivity to CD44 marker. Staining location was more to be in stellate reticulum-like (SR-like) cells when compared to ameloblast-like (AB-like) cells. Intense immunostaining was localized in the small tumor follicles, especially in SR-like cells situated in close vicinity of peripheral AB-like cells whereas mild intensity of staining was observed in keratinizing areas.
Conclusion: CSCs marker positive expression in benign tumor like ameloblastoma may be responsible for its aggressiveness and recurrence. CD44 marker may be of great value in predicting the biological behavior and growth potential of ameloblastoma.</description><subject>Ameloblastoma</subject><subject>Benign</subject><subject>Cancer</subject><subject>CD44 antigen</subject><subject>Ethylenediaminetetraacetic acid</subject><subject>Follicles</subject><subject>Immunoreactivity</subject><subject>Invasiveness</subject><subject>Original</subject><subject>Statistical analysis</subject><subject>Stem cell research</subject><subject>Stem cells</subject><subject>Tumor cells</subject><issn>0973-029X</issn><issn>1998-393X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNp9ks1u1DAUhS0EosPAC7BAkdiURQb_TuINUjWlUFRUFiB1ZznOdclMbA92wpS3x2HaaooQ8sKS_Z3je-8xQi8JXnCC2dt1cHa7-HT5-eyLIoIqUj1CMyJlXTLJrh6jGZYVKzGVV0foWUprjEXNBX2KjhiRnBJKZmh17tzoA9xsIabUBV8EWxjtDcQiDeAKA31fOB03-eB4dcr5m6LzhXbQh6bXaQhOP0dPrO4TvLjd5-jb2fuvq4_lxeWH89XJRWl4xW5KyTXUrCasXhrREN4sTUMY0zUAtzLXphtbVZRSbhopmla3wlhbyYa0FpYAbI7e7X23Y-OgNeCHqHu1jV2u75cKulMPb3z3XV2Hn2opeY3zTObo-NYghh8jpEG5Lk0Nag9hTIoyJiu55GJCX_-FrsMYfW5vorCoBMEH1LXuQXXehvyumUzVScVFzkJkeo4W_6DyasF1JniwXT5_IKB7gYkhpQj2vkeC1RS9-hO9Oow-i14dTudecpd1Bk73wC70Q0570487iCqzGx92_7FWHGN190_Yb-V-w1Y</recordid><startdate>20190901</startdate><enddate>20190901</enddate><creator>Vanje, Manjushri</creator><creator>Tanveer, Shahela</creator><creator>Ahmed, Syed</creator><creator>Kumar, Shravan</creator><creator>Vanje, Tejashree</creator><general>Wolters Kluwer India Pvt. Ltd</general><general>Medknow Publications and Media Pvt. Ltd</general><general>Medknow Publications & Media Pvt. Ltd</general><general>Wolters Kluwer - Medknow</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M2O</scope><scope>M7P</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20190901</creationdate><title>Immunoexperssion of cancer stem cell marker (CD44) in ameloblastoma</title><author>Vanje, Manjushri ; Tanveer, Shahela ; Ahmed, Syed ; Kumar, Shravan ; Vanje, Tejashree</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c473x-94ae8381386c5b14b6cb133a8ee4f9058abf772224cb95bdad5cff79b1dfe6ee3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Ameloblastoma</topic><topic>Benign</topic><topic>Cancer</topic><topic>CD44 antigen</topic><topic>Ethylenediaminetetraacetic acid</topic><topic>Follicles</topic><topic>Immunoreactivity</topic><topic>Invasiveness</topic><topic>Original</topic><topic>Statistical analysis</topic><topic>Stem cell research</topic><topic>Stem cells</topic><topic>Tumor cells</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Vanje, Manjushri</creatorcontrib><creatorcontrib>Tanveer, Shahela</creatorcontrib><creatorcontrib>Ahmed, Syed</creatorcontrib><creatorcontrib>Kumar, Shravan</creatorcontrib><creatorcontrib>Vanje, Tejashree</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>SciTech Premium Collection (Proquest) (PQ_SDU_P3)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>ProQuest research library</collection><collection>ProQuest Biological Science Journals</collection><collection>Research Library (Corporate)</collection><collection>Publicly Available Content Database (Proquest) (PQ_SDU_P3)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of oral and maxillofacial pathology : JOMFP</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Vanje, Manjushri</au><au>Tanveer, Shahela</au><au>Ahmed, Syed</au><au>Kumar, Shravan</au><au>Vanje, Tejashree</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Immunoexperssion of cancer stem cell marker (CD44) in ameloblastoma</atitle><jtitle>Journal of oral and maxillofacial pathology : JOMFP</jtitle><addtitle>J Oral Maxillofac Pathol</addtitle><date>2019-09-01</date><risdate>2019</risdate><volume>23</volume><issue>3</issue><spage>400</spage><epage>406</epage><pages>400-406</pages><issn>0973-029X</issn><eissn>1998-393X</eissn><abstract>Background: Ameloblastoma is the most frequently encountered benign, locally invasive tumor. Attempts to surgically resect the tumor often leave small islands of tumor, which later result in recurrence in 50%-90% of cases. This has raised questions regarding the tumor cell populations that are responsible for tumor growth and recurrence. In ameloblastoma, whether or not cancer stem-like cells are present remains undetermined. However, if cancer stem-like cells are present in ameloblastoma, it is important to identify which type of cell possesses the stem-like characteristics and is responsible for ameloblastoma progression and recurrence.
Aim: Our study aims at analyzing immunohistochemical staining to detect the expression of cancer stem cell (CSC) marker CD44 in relation to proliferative activity of tumor cells in histopathologically diagnosed cases of ameloblastoma variants and to derive a correlation between the CD44 expression and biologic behavior of the lesion.
Materials and Methods: A retrospective study, was conducted on total 25 cases ameloblastoma and were immunostained for CD44 expression. Results obtained were statistically analyzed.
Results: A positive correlation was observed between staining intensity of CD44 marker and the known biological behavior of the lesion. Intense staining reaction was found to be only in 8% cases, whereas 76% cases demonstrated moderate intensity and remaining 16% displayed mild immunoreactivity to CD44 marker. Staining location was more to be in stellate reticulum-like (SR-like) cells when compared to ameloblast-like (AB-like) cells. Intense immunostaining was localized in the small tumor follicles, especially in SR-like cells situated in close vicinity of peripheral AB-like cells whereas mild intensity of staining was observed in keratinizing areas.
Conclusion: CSCs marker positive expression in benign tumor like ameloblastoma may be responsible for its aggressiveness and recurrence. CD44 marker may be of great value in predicting the biological behavior and growth potential of ameloblastoma.</abstract><cop>India</cop><pub>Wolters Kluwer India Pvt. Ltd</pub><pmid>31942121</pmid><doi>10.4103/jomfp.JOMFP_152_17</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0973-029X |
| ispartof | Journal of oral and maxillofacial pathology : JOMFP, 2019-09, Vol.23 (3), p.400-406 |
| issn | 0973-029X 1998-393X |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6948039 |
| source | Medknow Open Access Medical Journals(OpenAccess); PubMed Central Open Access; PubMed Central; EZB Electronic Journals Library |
| subjects | Ameloblastoma Benign Cancer CD44 antigen Ethylenediaminetetraacetic acid Follicles Immunoreactivity Invasiveness Original Statistical analysis Stem cell research Stem cells Tumor cells |
| title | Immunoexperssion of cancer stem cell marker (CD44) in ameloblastoma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-17T19%3A24%3A47IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Immunoexperssion%20of%20cancer%20stem%20cell%20marker%20(CD44)%20in%20ameloblastoma&rft.jtitle=Journal%20of%20oral%20and%20maxillofacial%20pathology%20:%20JOMFP&rft.au=Vanje,%20Manjushri&rft.date=2019-09-01&rft.volume=23&rft.issue=3&rft.spage=400&rft.epage=406&rft.pages=400-406&rft.issn=0973-029X&rft.eissn=1998-393X&rft_id=info:doi/10.4103/jomfp.JOMFP_152_17&rft_dat=%3Cgale_pubme%3EA745199523%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2330575109&rft_id=info:pmid/31942121&rft_galeid=A745199523&rfr_iscdi=true |